drugset / Trial / NCT00242710

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

NCT00242710

Phase 3 Completed 1083 enrolled Pfizer
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.

Timeline

Start
2005-09
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified 20 mg Oral
Comparator MPA Unknown 1.5 mg Oral
Subject conjugated estrogens Other / unclassified 0.45 mg Oral
Subject conjugated estrogens Other / unclassified 0.625 mg Oral